Andrew Spencer
Overview
Explore the profile of Andrew Spencer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
258
Citations
9747
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashby M, Fleming S, Spencer A, Woollett A, Wright T
Intern Med J
. 2025 Mar;
PMID: 40056073
Background: The management of patients with haematological malignancies in rural and regional Australia is different to that in metropolitan centres due to many factors. Lower-intensity and easier-to-access treatments that are...
2.
Kazzi C, Simpson T, Abbott C, Wronski M, Seery N, Tan T, et al.
BMJ Neurol Open
. 2025 Feb;
7(1):e000927.
PMID: 39950093
Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common complication of chimeric antigen receptor (CAR) T-cell therapy. Current practice guidelines recommend the immune effector cell-associated encephalopathy (ICE) score for...
3.
Ho P, Quach H, Sidiqi M, Lee C, Butler J, Spencer A, et al.
Front Oncol
. 2025 Feb;
14:1535869.
PMID: 39906669
Background: Regulatory bodies have recently approved chimeric antigen receptor (CAR)-T cell therapies for patients with multiple myeloma (MM), but the treatment process involves complex decision making. To support the introduction...
4.
Bingham N, Shah J, Wong D, Lim S, Bergin K, Kalff A, et al.
Blood Cancer J
. 2025 Jan;
15(1):5.
PMID: 39799110
No abstract available.
5.
Olaisen C, Rost L, Sharma A, Sogaard C, Khong T, Berg S, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682151
: To examine the regulatory role of PCNA in MM, we have targeted PCNA with the experimental drug ATX-101 in three commercial cell lines (JJN3, RPMI 1660, AMO) and seven...
6.
Landgren C, Chari A, Cohen Y, Spencer A, Voorhees P, Sandhu I, et al.
Blood
. 2024 Dec;
PMID: 39652826
Early intervention of smoldering multiple myeloma (SMM) may delay progression to multiple myeloma. Here, we present the final analysis of the phase 2 CENTAURUS study (NCT02316106). In total, 123 patients...
7.
Lim K, Wellard C, Moore E, Ninkovic S, Chng W, Spencer A, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
PMID: 39616008
No abstract available.
8.
Zhao J, Khong T, Gorniak M, Khaled A, McDonald Z, Reynolds J, et al.
Haematologica
. 2024 Nov;
110(3):764-767.
PMID: 39506908
No abstract available.
9.
Dillon H, Saner N, Ilsley T, Kliman D, Foulkes S, Brakenridge C, et al.
Circulation
. 2024 Nov;
151(4):292-308.
PMID: 39492713
Background: Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. We...
10.
Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, et al.
Future Oncol
. 2024 Sep;
20(38):3043-3063.
PMID: 39287147
What Is This Summary About?: This summary describes the first analysis of the PERSEUS study, which looked at adults with multiple myeloma that had never been treated before, also called...